Choose a language and wait for the translated text.
Shots:
Bristol Myers Squibb has decided not to advance PRX019 (BMS-986495) further in the clinic following an internal strategic review, as disclosed by Prothena in an SEC filing; the PRX019 global license agreement will terminate on Jan 28, 2027
BMS licensed exclusive global rights to PRX019 in May 2024 for $80M upfront; with the termination, BMS will not owe Prothena the remaining up to $617.5M in milestones or any royalties
Prothena completed the P-I trial of PRX019 in H1β26, which showed a benign safety profile, no immunogenicity & dose-dependent PK/PD effects; BMS continues developing moponetug in the P-II (TargetTau-1) trial for early Alzheimerβs disease
Ref: SEC (Prothena Form 8-K) | Image: Bristol Myers Squibb & Prothena | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Bristol Myers Squibb Discontinues Development of Prothena-Partnered PRX019 and Terminates License Agreement appeared first on PharmaShots.
